论文部分内容阅读
目的 :评价细胞因子诱导的杀伤细胞 (cytokineinducedkiller ,CIK)治疗急性白血病患者的有效性及安全性。方法 :采用血细胞分离机大量采集患者的外周血单个核细胞 ,再用抗CD3单抗、白细胞介素 2、干扰素γ培养10d左右 ,将细胞洗涤后经静脉回输给患者。结果 :37例急性白血病患者共接受 5 8疗程CIK治疗。 34例血液学缓解期接受CIK治疗患者的 3年持续完全缓解 (continuouscompleteremission ,CCR)概率为 75 % ,CIK治疗后的中位CCR期为 2 6月 (1～ 5 9月 )。经 1疗程CIK治疗后 ,2例 (2 /3)肿大的脾明显缩小 ,均CCR至今 (12 ,16月 ) ;8例(8/8)骨髓残留的异常染色体和 /或基因标志消失。CIK输注后除一过性发热 ,畏寒、疲乏外 ,无其它严重副作用。结论 :自体CIK细胞治疗具有明显清除微小残留白血病细胞、防止复发的作用 ,静脉输注安全
Objective: To evaluate the efficacy and safety of cytokine-induced killer (CIK) therapy in patients with acute leukemia. METHODS: A large number of patients’ peripheral blood mononuclear cells were collected by a blood cell separator, and then cultured with anti-CD3 monoclonal antibody, interleukin-2 and interferon gamma for about 10 days. The cells were washed and returned to the patient by intravenous infusion. Results: A total of 37 patients with acute leukemia received a total of 58 CIK treatments. The probability of three-year continuous complete remission (CCR) was 34% in 34 patients treated with CIK during hematologic remission, and the median CCR period after CIK treatment was 2 June (January-September). After 1 course of CIK treatment, 2 cases (2/3) of the enlarged spleen were significantly reduced, and all cases had CCR (12, 16 months); 8 cases (8/8) of residual abnormal chromosome and/or gene markers disappeared. After the CIK infusion, there was no other serious side effects except for transient fever, chills and fatigue. Conclusion : Autologous CIK cell therapy has the effect of clearing minimal residual leukemia cells and preventing recurrence. Intravenous infusion safety